SoundView Technology Group Issues NXT-ID Update ; Wocket

New Post Public Reply Private Reply Replies (0) Message Board
Roger Wilco
SoundView Technology Group Issues NXT-ID Update ; Wocket Working Towards CES

pr-newswire3-60x27_151656.gif
http://finance.yahoo.com/news/soundview-techn...00702.html
BOSTON, Dec. 3, 2014 /PRNewswire/

-- SoundView Technology Group (http://soundview.co) releases the following market and company update for NXT-ID, Inc. (NASDAQ:NXTD and NXTDW).

Market & Company UpdateWOCKET WORKING TOWARDS CESKRIS TUTTLE – DECEMBER 1, 2014

Investors have come to realize that the "revolutionary" Apple Pay is a continuation of the existing credit/debit card model and payment infrastructure. It adds a layer of security and convenience but the back end is still the same. In other words, we are digitizing the plastic part of the existing payment system rather than doing something profoundly new and different.

There is a simpler and more direct way to digitize your credit cards. Using a digital wallet like the Wocket, the myriad separate plastic cards are replaced with one reprogrammable card that behaves as whatever card the user selects. Not only does this also use the same back end systems in place, but it also works with all the existing front-end systems for credit and debit cards.

The_Home_Depot-logo-D9A04F4616-seeklogo.com.gif

Major retailers like Home Depot have launched major investments to upgrade their own infrastructure with security enhancements that will work with all transactions. This is key point – retailers need to offer safe, secure and smooth checkout for all customers and payment types, not just Apple Pay.

wocket-ps.jpg

So for us, this puts solutions like the Wocket in a favorable position with respect to other solutions involving all non-cash transactions. Consumers can keep their existing cards, pay any merchant, and have no worries about security, fraud, battery life or other "technical issues" that bedevil many existing phone-based offerings from QR codes to NFC.

As many failed Kickstarter projects attest – it's exponentially more difficult to launch a real consumer product at scale than make a slick video showing a magical solution, like "Coin" for example. When you get into the nitty-gritty of different cards and formats needed to support all cards and not just the easy ones, some real technical innovation is needed.

CES-2015-e1404787367173.jpg

NXT-ID has been hard at work for months, finalizing their Wocket so it's ready for CES in early January. As they have worked through the design, they have overcome thorny issues ranging from accurately capturing different types of cards to engineering the Wocket card to contain all the needed electronics, yet still remain just a millimeter thick.

We still expect their initial production run to happen during December and for first commercial units to be in use during January. CES will be a coming out party for NXT-ID with mainstream buyers, partners and the broader media outlets. Based on what we know, the feedback should be validating and positive, but we will have a better gauge of that post-event.

NXT-ID has been preparing their production facilities to ramp up to much higher volumes, which should be able to meet initial consumer demand and improve steadily during 2015. A review of our current IV estimate (attached) indicates the planned ramp provides plenty of room for NXT-ID to exceed our expectations, as long as they continue to execute and consumer acceptance and adoption provides the market opportunity.



Stock Conclusion

The market has been taking a "wait and see" attitude with respect to the shares since the end of the summer when it became clear that commercial volumes wouldn't happen until 2015. We won't try and predict market sentiment on NXTD, but if the company meets current plans for early commercial units by December and has a solid debut at CES, the shares will have put in a bottom.

We plan to share more data points in December as production work continues. Our IV of $8.18 makes the shares very attractive, albeit with some expectation of success built into the estimate. If the company meets their plans in 2015, it would push our IV estimate up to $17.42.

It's also a good time to keep a careful eye out for indiscriminate tax-loss selling during times when volumes are low – it can create some extra volatility. Based on the outlook for next year, we'd be looking to exploit that opportunity should it materialize.

The NXT research update (PDF) is also published and available here:
http://s3.amazonaws.com/PUBLISHED/NXT-ID_NXTD...14_PUB.pdf

Past reports and related research can be found on our website at:
http://soundview.co/infosec

NXTID_Star-tag.png

About NXT- ID Inc. - Mobile Security for a Mobile World: (NXTD) (NXTDW):

NXT-ID, Inc.'s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.

http://www.wocketwallet.com/

NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 5

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Flavors of Portugal at the 2025 Port Wine Fest

Updated Category News Views 380

Port Wine Fest: A Celebration of Portuguese Culture The Port Wine Fest is an exciting festival dedicated to showcasing Portuguese wines and cuisine. In 2025, it will embark on its third edition with events scheduled across various vibrant cities, including San Francisco, Chicago, and New York City, creating an unforgettable experience that combines culture, food, and fine...

Continue Reading
Earnings Projections for 5E Advanced Materials to Watch

Updated Category News Views 118

Understanding 5E Advanced Materials’ Earnings Expectations 5E Advanced Materials (NASDAQ: FEAM) is gearing up to unveil its quarterly earnings report soon. Investors are keenly awaiting the details, as quarterly performance can significantly influence stock trends and market sentiment. Projected Earnings per Share Analysts are estimating an earnings per share (EPS) of...

Continue Reading
Verano Launches Adult Cannabis Sales in Connecticut's Waterbury

Updated Category News Views 111

Verano Launches Adult Use Cannabis Sales at Zen Leaf Waterbury Zen Leaf Waterbury has achieved a significant milestone by transitioning its dispensary from medical-only sales to hybrid sales, allowing for adult use cannabis sales in Connecticut. Location and Accessibility of Zen Leaf Waterbury Conveniently located at 237 East Aurora Street in Waterbury, the fifth largest...

Continue Reading
Innovative Medical Education Suite Introduced by Treatment.com AI

Updated Category News Views 176

Revolutionizing Medical Education with AI Integration Treatment.com AI Inc. is making strides in medical education by unveiling a cutting-edge platform designed to enhance clinical skills training. This innovation aims to provide a more immersive and effective educational experience for medical students. The newly launched Medical Education Suite (MES) represents a...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 24

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading